Inspira(TM) Technologies Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Inspira(TM) Technologies Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / December 22, 2022 / RedChip Companies will air a new interview with Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, on The RedChip Money Report on Bloomberg TV, this Saturday, December 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
佛罗里达州奥兰多/ACCESSWIRE/2022年12月22日/红筹公司将于本周六，12月24日晚7点，在彭博电视台播出对呼吸支持技术公司Inspira Technologies Oxy B.H.N.Ltd.(纳斯达克代码：IINN)(以下简称“公司”或“Inspira Technologies”)的新一轮访谈。东部时间(ET)。据估计，全美约有7300万个家庭可以收看彭博电视。
Interview highlights:
采访亮点：
In the exclusive RedChip Money Report interview, Inspira Technologies' Co-Founder & President Joe Hayon discusses how Inspira's technology could reduce the need for invasive mechanical ventilation, plans to begin human studies at leading medical centers, how the technology could become the new potential standard of care for acute respiratory failure, and much more.
在《红筹资金报告》的独家访谈中，Inspira Technologies的联合创始人兼总裁Joe·海扬讨论了Inspira的技术如何减少对有创机械通气的需求，计划在领先的医疗中心开始人体研究，该技术如何成为急性呼吸衰竭的新潜在护理标准，等等。
Access this interview in its entirety at
访问此访谈全文，请访问
About The RedChip Money Report
关于红筹资金报告
The RedChip Money Report is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today. "The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
红筹资金报告由红筹公司制作，该公司是一家国际投资者关系和媒体公司，拥有30年的经验，专注于今天发现明天的蓝筹股。《红筹资金报告》提供了关于小盘股投资的精辟评论、华尔街分析师的采访、金融书评，以及对上市公司高管的专题采访。
About Inspira Technologies
关于Inspira技术
Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company is researching and developing a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while minimizing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and have not been approved by any regulatory entity.
Inspira Technologies是一家在呼吸治疗领域创新的医疗技术公司。该公司正在研究和开发一种突破性的增强呼吸技术(INSPIRA ART)，旨在重新平衡患者的血氧饱和度水平。这项技术可能使患者在治疗期间保持清醒，同时最大限度地减少对需要插管和药物诱导昏迷的高度侵入性、高风险和昂贵的机械通风系统的需求。该公司的产品尚未在人体上进行测试或使用，也未获得任何监管实体的批准。
For more information, please visit our corporate website:
欲了解更多信息，请访问我们的公司网站：
About RedChip Companies
关于红筹公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
红筹公司是一家拥有5000美元股份的公司，是一家专注于微市值和小盘股公司的国际投资者关系、媒体和研究公司。30年来，红筹为客户提供了具体、可衡量的结果。我们的时事通讯《红筹资金报告》每周在线发送给60,000名投资者。红筹为小盘股和小盘股公司开发了业内最全面的服务平台。这些服务包括：其股票研究的全球分销网络；在美国主要城市的零售和机构路演；面向股票经纪人、RIA、机构和家族理财室的对外营销；已产生数百万独特投资者观点的数字媒体投资者关系平台；投资者网络研讨会和团体电话会议；每周在彭博美国播出的电视节目“红筹资金报告”；本地和全国市场的电视广告；企业和产品视频；网站设计；以及传统投资者关系服务，其中包括新闻稿撰写、投资者演示文稿的开发、季度电话会议脚本编写、战略咨询、融资等。
To learn more about RedChip's products and services, please visit:
要了解更多有关红筹公司产品和服务的信息，请访问：
"Discovering Tomorrow's Blue Chips Today"
“今天发现明天的蓝筹股”
Forward Looking Statements
前瞻性陈述
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when its regulatory strategy, the expected timing of its clinical study, the expected benefits to patients of its products, the belief that the potential use of the HYLA blood sensor for multiple hospital settings increases its potential commercial appeal as a standalone device, that it expects to add the HYLA blood sensor to its INSPIRA ART system and that the HYLA blood sensor has significant potential to make a meaningful impact on real-time patient monitoring. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website, www.sec.gov
本新闻稿包含符合美国联邦证券法的明示或暗示的前瞻性陈述。这些前瞻性陈述及其影响仅基于公司管理层目前的预期，受许多因素和不确定因素的影响，这些因素和不确定性可能导致实际结果与前瞻性陈述中所描述的大不相同。例如，该公司在其监管战略、临床研究的预期时间、其产品对患者的预期益处等方面使用前瞻性陈述，认为Hyla血液传感器在多家医院环境中的潜在使用增加了其作为独立设备的潜在商业吸引力，预计将Hyla血液传感器添加到其INSPIRA ART系统中，Hyla血液传感器具有对患者实时监测产生重大影响的巨大潜力。这些前瞻性陈述及其影响完全基于公司管理层目前的预期，受许多因素和不确定因素的影响，这些因素和不确定性可能导致实际结果与前瞻性陈述中所描述的大不相同。除非法律另有要求，否则公司没有义务公开发布对这些前瞻性陈述的任何修订，以反映本前瞻性陈述之后发生的事件或情况，或反映意外事件的发生。有关影响公司的风险和不确定因素的更详细信息，载于公司提交给美国证券交易委员会(“美国证券交易委员会”)的截至2021年12月31日的财政年度20-F表格年度报告中的“风险因素”标题下，该报告可在美国证券交易委员会的网站www.sec.gov上查阅。
Contact:
联系方式：
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
IINN@redchip.com
戴夫·金特里
红筹公司。
1-800-红筹(733-2447)
或407-491-4498
邮箱：iinn@redchip.com
SOURCE: RedChip
资料来源：红筹公司